Disruptive Insights Group launched a new web-based healthcare research platform and Payer Insights as part of the company's product suite.
Healthcare payments in the United States are expected to top $5 trillion by 2022, making the payer's perspective increasingly important. Payers are using quality of care outcomes information to guide their decision-making processes for payment. There is also an influx of unexpected costs that put health plans at risk and could restrict access to therapies.
Disruptive Insight's mission is to turn the "blind spots" in payer process and pricing into meaningful insight for investors and decision-makers. Disruptive Inisghts trades customer engagement for insight from a diverse group of medical directors for leading health plans, PBMs, accountable care organizations, integrated networks and employer coalitions as part of Payer Insights.
The company's first two reports focus on spine surgery and hip/knee surgery. The company's products were previously limited to third party resellers, but the new website opens up new relationship possibilities. The company has positive feedback on the report and plans to continue expanding its network of healthcare influencers and stakeholders.
"The launch of our website and Payer Insights allows us to extend these conversations and products to new customers in new areas of healthcare," said Managing Editor Richard Sims. "We look forward to engaging our customers at every stage of the diligence process."
The reports provide deep and ongoing insight into management strategies for specific therapeutic categories. Payer Insights also offers a view into current and expected trends in payer management and reimbursement as the healthcare system moves more towards value-based models, detailing the impact of payer management and contextualizing payer behavior.
The questions Payer Insights can answer include:
1. Are payers looking to increase management focus in a given therapy?
2. What are payer expectations for overall surgery costs for a therapy in the near future?
3. Will alternative reimbursements come to a therapy? How soon? To what degree?